Results 71 to 80 of about 25,818 (186)

Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase-Positive Lymphoma Patients [PDF]

, 2017
Anaplastic lymphoma kinase (ALK)-positive lymphomas respond to chemotherapy, but relapses, which bear a poor prognosis, occur. Crizotinib inhibits ALK in vitro and in vivo and was administered as monotherapy to 11 ALK+ lymphoma patients who were ...
Antolini, Laura, Bernard, Lea, Ceccon, Monica, Chiriano, Gianpaolo, Cohen, Amos M., Deeren, Dries, Farina, Francesca, Gambacorti Passerini, Carlo, Giudici, Giovanni, Grube, Matthias, Guerra, Luca, King, Michael H., Messa, Cristina, Mologni, Luca, Mussolin, Lara, Ordemann, Rainer, Piazza, Rocco, Redaelli, Sara, Sala, Elena, Stasia, Alessandra, Steurer, Michael   +20 more
core  

The Mutation Patterns of MET Gene in Lung Cancer and Brain Tumors: Clinical and Therapeutic Implications

Cancer Medicine, Volume 15, Issue 1, January 2026.
ABSTRACT Objectives MET aberrations are capable of triggering oncogenesis through multiple clinical significance genomic alterations. In non‐small cell lung cancer, MET exon 14 skipping and MET amplification confer sensitivity to MET tyrosine kinase inhibitors. The MET gene is also one of the druggable genes in high‐grade gliomas. However, a systematic
Yu Zhang, Ningning Luo, Minghui Ge, Yanxiang Zhang, Dongsheng Chen, Yongmeng Li   +5 more
wiley   +1 more source

Cyclosporine A sensitizes lung cancer cells to crizotinib through inhibition of the Ca2+/calcineurin/Erk pathwayResearch in context

EBioMedicine, 2019
Background: Crizotinib has potent anti-tumor activity in patients with advanced MET-amplified non-small cell lung cancer (NSCLC). However, the therapeutic effect is still not satisfying. Thus, developing approaches that improve the efficacy of crizotinib
Zhen Liu, Liming Jiang, Yiran Li, Binbin Xie, Jiansheng Xie, Zhanggui Wang, Xiaoyun Zhou, Hanliang Jiang, Yong Fang, Hongming Pan, Weidong Han   +10 more
doaj   +1 more source

Anaplastic large cell lymphoma in paediatric and young adult patients. [PDF]

, 2016
Anaplastic large cell lymphoma (ALCL) is a heterogeneous disease of debateable origin that, in children, is largely anaplastic lymphoma kinase (ALK) positive with aberrant ALK activity induced following the formation of chromosomal translocations. Whilst
Agnelli, Ait-Tahar, Ait-Tahar, Alexander, Ambrogio, Bai, Bai, Bartlett, Benharroch, Bonzheim, Brugieres, Brugieres, Brugieres, Brugieres, Chiarle, Chiarle, Cools, Crescenzo, Damm-Welk, Damm-Welk, Deley, Deley, Duvic, Elias, Eyre, Falini, Falini, Fanale, Feldman, Feldman, Gambacorti Passerini, Gambacorti Passerini, Gascoyne, Hanahan, Hoareau-Aveilla, Hoch, Katayama, Kempf, Kenner, Kinney, Laimer, Laly, Lamant, Lamant, Lamant, Lamant, Laurent, Laurent, Laver, Leventaki, Liang, Lowe, Malcolm, Marzec, Marzec, Marzec, Mason, McDonnell, Merkel, Merkel, Mori, Morris, Mosse, Moti, Mussolin, Mussolin, Parrilla Castellar, Passoni, Passoni, Pileri, Pro, Pulford, Raica, Richly, Rolland, Rosenwald, Rosolen, Ruf, Salaverria, Savage, Schmitz, Seidemann, Sibon, Slupianek, Stein, Suzuki, Swerdlow, Tanaka, Tanaka, Tort, Touriol, Trinei, Turner, Turner, Vasmatzis, Vassallo, Wencker, Willemze, Williams, Williams, Woessmann, Woessmann, Wrobel, Ye, Youssif, Zhang, Zhang   +106 more
core   +1 more source

ALK‐Positive Histiocytosis With Unilateral Breast Involvement: A Case Report

Clinical Case Reports, Volume 14, Issue 1, January 2026.
ABSTRACT APH is a rare disorder characterized by the proliferation of ALK‐expressing histiocytes with variable anatomical involvement; however, mammary involvement is exceptionally rare. A 32‐year‐old woman presented with a painless right breast mass. Ultrasound identified a 9 × 8 mm hypoechoic nodule, categorized as BI‐RADS 4A.
Xuechun Liu, Dong Ren, Yanfang Liang
wiley   +1 more source

Comparative Analysis of a Dual DNA–RNA Panel and a DNA‐Only Panel for Sarcoma: Real‐World Data From a Nationwide Genomic Database

Cancer Science, Volume 117, Issue 1, Page 156-168, January 2026.
Dual DNA–RNA panel with matched tumor–normal testing may improve diagnostic accuracy and inform treatment decisions in the routine clinical management of sarcoma. ABSTRACT Next‐generation sequencing‐based comprehensive cancer genomic profiling is promising in cancer management; however, most studies rely on tumor‐only DNA panels from single ...
Eiji Nakata, Kiichiro Ninomiya, Tatsunori Osone, Daisuke Ennishi, Shuta Tomida, Tomohiro Fujiwara, Toshiyuki Kunisada, Mashu Futagawa, Akira Hirasawa, Shinichi Toyooka, Toshifumi Ozaki   +10 more
wiley   +1 more source

Systemic Surveillance Guidelines for Uveal Melanoma: A Systematic Review

Clinical &Experimental Ophthalmology, Volume 54, Issue 1, Page 99-112, January/February 2026.
ABSTRACT Background Uveal melanoma (UM) is the most common primary intraocular tumour. Despite effective local therapies, UM has a high risk of metastatic recurrence, most frequently to the liver. A significant proportion of patients treated definitively for primary UM eventually experience metastatic disease. Systemic surveillance to detect recurrence
Farzana Y. Zaman, Aisha Ghaus, Mark Shackleton, Damien Kee, Anthony M. Joshua, Roderick O'Day, Malaka Ameratunga   +6 more
wiley   +1 more source

Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong

Cost Effectiveness and Resource Allocation, 2020
Introduction Lower-dose ceritinib (450 mg) once-daily with food was approved in 2018 in Hong Kong (HK) for first-line treatment of patients with anaplastic lymphoma kinase-positive (ALK +) advanced non-small cell lung cancer (NSCLC).
Herbert H. Loong, Carlos K. H. Wong, Linda K. S. Leung, Catherine P. K. Chan, Andrea Chang, Zheng-Yi Zhou, Jipan Xie, Meaghan Gibbs   +7 more
doaj   +1 more source

Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma. [PDF]

, 2015
Uveal melanoma patients with metastatic disease usually die within one year, emphasizing an urgent need to develop new treatment strategies for this cancer.
Aplin, Andrew E., Cheng, Hanyin, Kageyama, Ken, McCue, Peter, Ozaki, Shinji, Sato, Takami, Terai, Mizue   +6 more
core   +2 more sources

Molecular Insights and Therapeutic Innovations in Cervical Cancer: Emerging Drug Targets

Advances in Pharmacological and Pharmaceutical Sciences, Volume 2026, Issue 1, 2026.
Cervical cancer is a significant global health challenge, ranking as the fourth most prevalent cancer among women worldwide. While human papillomavirus infection is the primary cause, the disease’s progression involves complex molecular mechanisms.
Abhijit Debnath, Rajesh Kumar Singh, Rupa Mazumder, Arpita Dua, Pankaj Kumar Tyagi, Anil Kumar Singh, Kuldeep Singh   +6 more
wiley   +1 more source